NovaBay Pharmaceuticals Announces Major Strategic Shift: Name Change to Stablecoin Development Corporation, SKY Token Holdings, and Ticker Symbol Update

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced a transformative strategic shift, marking a significant pivot in its business operations and market identity. The company will change its name to Stablecoin Development Corporation and update its ticker symbol to SDEV. This move, along with substantial SKY token holdings and an updated digital asset strategy, has major implications for shareholders and the company’s future direction.

Key Highlights of the Announcement

• Corporate Name Change: NovaBay Pharmaceuticals, Inc. will formally change its name to Stablecoin Development Corporation, signaling a shift from traditional pharmaceuticals to a focus on stablecoin and digital asset development.
• Ticker Symbol Change: The company’s common stock will cease trading under the ticker “NBY” and begin trading as “SDEV” on the NYSE American. This change is scheduled to take effect as of the market open on April 3, 2026.
• SKY Token Holdings and On-Chain Staking: As of March 16, 2026, the company holds approximately 2.06 billion SKY tokens and is actively engaged in on-chain activities, including staking, within the Sky protocol ecosystem.
• Strategic Investment Transaction Update: The company provided an update on its previously announced strategic investment transaction, emphasizing a focus on protocol-aligned digital assets and staking rewards.
• Tiered Warrant Structure: Warrants issued in a January 2026 private placement become exercisable in sequential tranches over an extended period, resulting in a weighted-average delay of approximately 9.9 months before all underlying shares could become eligible for issuance. This is designed to support an orderly market profile as the company executes its new strategy.
• Volume Limitation Covenants: Post-issuance trading covenants restrict each purchaser’s aggregate daily sales (including affiliates) to 10% of SDEV’s 30-day average daily trading volume following any warrant exercise. This applies uniformly to all purchasers and aims to promote stable market dynamics.
• Disclosure Channels: Material information will continue to be disclosed through SEC filings, the company’s website, press releases, public conference calls/webcasts, and official social media accounts.

What Shareholders Need to Know (Price-Sensitive Information)

• This is a fundamental business transformation: The company is shifting away from pharmaceuticals into the digital asset and stablecoin sector. Such a significant change in focus could materially affect the company’s future earnings potential, risk profile, and investor base.
• SKY Token Holdings: The company’s large holdings in SKY tokens and participation in staking activities expose shareholders to the risks and rewards of the volatile digital asset market, in addition to traditional equity risks.
• Potential for Share Price Volatility: The ticker symbol change, new business direction, and digital asset disclosures could attract new investors, but may also prompt existing shareholders to reevaluate their positions, potentially leading to share price volatility.
• Warrant Structure and Trading Limitations: The staggered release of new shares and imposed trading volume restrictions for warrant holders are specifically designed to prevent sudden dilution and disorderly trading, which could otherwise pressure the share price.
• Regulatory and Market Risks: The company highlights risks including digital asset market volatility, regulatory uncertainties regarding digital assets and staking, protocol governance changes, and cybersecurity threats. These factors could have material impacts on future performance and share value.

Further Information

The company encourages investors to monitor all official disclosure channels, including SEC filings, press releases, and its official website and social media, for further updates. The company’s forward-looking statements are subject to risks and uncertainties, as detailed in its most recent Annual Report on Form 10-K and other filings.

Contact Information

Chief Financial Officer: Tommy Law
Email: [email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially. Investors should review all company filings and consult with professional advisors prior to making any investment decisions. The author assumes no responsibility for investment actions taken based on this article.

View NovaBay Pharmaceuticals, Inc. Historical chart here